Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Accounts Payables (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Accounts Payables for 5 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Accounts Payables fell 13.06% to $1.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.1 million, a 13.06% decrease, with the full-year FY2024 number at $3.0 million, up 127.17% from a year prior.
  • Accounts Payables was $1.1 million for Q3 2025 at Werewolf Therapeutics, down from $2.8 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $3.2 million in Q2 2021 to a low of $986000.0 in Q1 2025.
  • A 5-year average of $1.8 million and a median of $1.5 million in 2024 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: plummeted 42.47% in 2023, then surged 127.17% in 2024.
  • Werewolf Therapeutics' Accounts Payables stood at $2.0 million in 2021, then crashed by 40.06% to $1.2 million in 2022, then increased by 9.42% to $1.3 million in 2023, then skyrocketed by 127.17% to $3.0 million in 2024, then plummeted by 64.48% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Accounts Payables are $1.1 million (Q3 2025), $2.8 million (Q2 2025), and $986000.0 (Q1 2025).